Athersys (NASDAQ:ATHX) released its quarterly earnings results on Wednesday, May 8th. The biopharmaceutical company reported ($0.09) earnings per share for the quarter, hitting the consensus estimate of ($0.09), Morningstar.com reports. Athersys had a negative net margin of 109.78% and a negative return on equity of 58.10%. The business had revenue of $1.45 million for the quarter.
Shares of ATHX stock opened at $1.66 on Friday. The company has a market cap of $248.64 million, a P/E ratio of -9.22 and a beta of 0.48. Athersys has a 12 month low of $1.35 and a 12 month high of $3.09.
Several hedge funds have recently made changes to their positions in ATHX. Amalgamated Bank bought a new stake in Athersys during the 4th quarter worth approximately $25,000. Acadian Asset Management LLC bought a new stake in Athersys during the 1st quarter worth approximately $30,000. ExodusPoint Capital Management LP bought a new stake in Athersys during the 1st quarter worth approximately $32,000. Mercer Global Advisors Inc. ADV bought a new stake in Athersys during the 1st quarter worth approximately $36,000. Finally, BNP Paribas Arbitrage SA increased its holdings in Athersys by 62,382.1% during the 1st quarter. BNP Paribas Arbitrage SA now owns 24,368 shares of the biopharmaceutical company’s stock worth $37,000 after acquiring an additional 24,329 shares during the period. Institutional investors own 19.68% of the company’s stock.
WARNING: This piece of content was first posted by Rockland Register and is owned by of Rockland Register. If you are reading this piece of content on another site, it was illegally stolen and reposted in violation of U.S. & international copyright & trademark legislation. The legal version of this piece of content can be viewed at https://rocklandregister.com/2019/06/01/athersys-athx-releases-earnings-results-meets-expectations.html.
Athersys, Inc, a biotechnology company, focuses on the research and development activities in the field of regenerative medicine. Its clinical development programs are focused on treating neurological conditions, cardiovascular diseases, inflammatory and immune disorders, and pulmonary and other conditions.
Recommended Story: Why are analyst ratings important in trading stocks?
Receive News & Ratings for Athersys Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Athersys and related companies with MarketBeat.com's FREE daily email newsletter.